Exp Cell Res 1998, 241 (2) : 394–403.CrossRefPubMed 7. Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, Mittelkötter U, Uhl W, Chromik AM: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res 2008, 27: 82.CrossRefPubMed 8. Gurr JR, Bau DT, Liu F, Lynn S, Jan KY:
Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells. Mol Pharmacol 1999, 56 (1) : 102–109.PubMed KPT-330 chemical structure 9. Dong JT, Luo XM: Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res 1993, 302 (2) : 97–102.CrossRefPubMed 10. Ling YH, Jiang
JD, Holland JF, Perez-Soler R: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002, 62 (3) : 529–538.CrossRefPubMed 11. Chen GQ, Fedratinib Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z: n vitro studies on cellular and molecular mechanisms of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia: As 2 O 3 check details induces NB4 cell apoptosis U0126 order with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88 (3) : I1052–1061. 12. Kroemer G, de The H: Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999, 91 (9) : 743–745.CrossRefPubMed 13. Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, Sekhar KR, Gleave M, Freeman M, Lu B: Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
Int J Radiat Oncol Biol Phys 2005, 63 (4) : 1228–1236.CrossRefPubMed 14. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer research 2004, 64 (17) : 6174–6182.CrossRefPubMed 15. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E: A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008, 14 (3) : 833–839.CrossRefPubMed 16. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH: Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Molecular cancer therapeutics 2003, 2 (11) : 1155–1164.PubMed 17.